Brian Park, PharmD

Brian Park, PharmD

Drug Information Specialist https://www.empr.com
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Opdivo Evaluated as First Line Tx in Unresectable Hepatocellular Carcinoma Trial

Bristol-Myers Squibb announced topline results from the CheckMate-459 phase 3 trial of Opdivo (nivolumab) as first line treatment in patients with unresectable hepatocellular carcinoma (HCC). The CheckMate-459 trial was a multicenter, open label, randomized study that evaluated the efficacy of Opdivo compared with sorafenib in patients with unresectable HCC. Patients were treated until disease progression…

Adeno-Associated Virus 9 Gene Therapy Granted Fast Track Status for CLN1 Disease

The Food and Drug Administration has granted Fast Track designation to ABO-202 (Abeona Therapeutics Inc), a one-time adeno-associated virus 9 (AAV9) gene therapy for the treatment of CLN1 disease, also known as infantile neuronal ceroid lipofuscinosis or infantile Batten disease. CLN1 disease is a rapidly-progressing rare lysosomal storage disease caused by a defect in the…

Indication(s): Adjunct to diet: To reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.

Livalo Approved for Pediatric Patients With Heterozygous Familial Hypercholesterolemia

The Food and Drug Administration (FDA) has approved Livalo (pitavastatin; Kowa Pharmaceuticals America, Inc.) for use in pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB). The approval was based on a double blind, placebo controlled, 12-week trial…

Antibiotics

Treatment Options for Methicillin-Resistant Staphylococcus Aureus Pneumonia Evaluated

Evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia with trimethoprim-sulfamethoxazole (TMP-SMX), clindamycin, doxycycline, or minocycline was found to be based on limited data, according to a systematic review published in the Annals of Pharmacotherapy. Currently, the Infectious Disease Society of America (IDSA) recommends vancomycin and linezolid for the treatment of MRSA pneumonia, although…